<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>8925984</identifier>
<setSpec>0300-9041</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Bailón, R</dc:author>
<dc:author>Izquierdo, J C</dc:author>
<dc:author>Daza, M</dc:author>
<dc:author>Carranza-Lira, S</dc:author>
<dc:author>Morán, C</dc:author>
<dc:description xml:lang="en">Nine patients in which an intranasal GnRH agonist analog (napharelin acetate) was administered with the purpose of decreasing the size of the myomas, were studied. In all a decrement in uterine and myoma size was observed. The FSH levels decreased since the first treated cycle, whereas LH and E2 levels initially increase, but finally decreased. The patients had menstrual bleeding between four and eight weeks after napharelin withdrawal. The mentioned results elicit the effectivity of GnRH agonist analog for leomyomata treatment.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>1996 Aug </dc:date>
<dc:title xml:lang="es">Uso de análogos de GnRH por vía nasal en el tratamiento de miomatosis uterina.</dc:title>
<dc:title xml:lang="en">[Intranasal administration of GnRH in the treatment of uterine myomatosis].</dc:title>
<dc:publisher>Ginecologia y obstetricia de Mexico</dc:publisher>
</metadata>
</record>
</pubmed-document>
